Direkt zum Inhalt
Merck
  • [The prevention of the development of the collagen-induced microembolic syndrome by decreasing the hydrodynamic resistance of the blood with special polymers under flow].

[The prevention of the development of the collagen-induced microembolic syndrome by decreasing the hydrodynamic resistance of the blood with special polymers under flow].

Patologicheskaia fiziologiia i eksperimental'naia terapiia (1991-07-01)
I L Konorova, S E Akopov, E S Gabrielian, I V Gannushkina
ZUSAMMENFASSUNG

The search for antiaggregatory compounds is undertaken, as a rule, under in vitro conditions which do not reflect the dynamics of the real process. The present work deals with study of the peculiarities of the development of the collagen induced microembolic syndrome and the effect produced on it by hydrodynamic resistance reducing polymers under conditions modelling real circulation. The authors show the formation of a developed microembolic syndrome under the effect of collagen with accumulation of vasoconstrictors in the environment and increase of red cell hemolysis. Reduction of blood flow turbulence by the addition of solutions of neutral high-molecular linear polymers revealed the inhibiting effect of these polymers on the development of intracellular aggregate formation and concomitant red cell microhemolysis, which was attended by sharp reduction of thromboxane A2 production in the experiment. The authors show the significance of hemodynamic conditions in the development of the microembolic syndrome and the possibility of preventing it under conditions of modification of the blood flow with polymers, which may be of high prophylactic importance.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Poly(ethylenglykol), average Mn 400
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 8,000
Sigma-Aldrich
Poly(ethylenglykol), average mol wt 8,000, powder
Sigma-Aldrich
Poly(ethylenglykol), average Mn 6,000
Sigma-Aldrich
Poly(ethylenglykol), average Mn 3,350, powder
Sigma-Aldrich
Poly(ethylenoxid), average Mv 100,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 4,000
Sigma-Aldrich
Poly(ethylenoxid), average Mv 600,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenglykol), average Mn 300
Sigma-Aldrich
Poly(ethylenglykol), average Mn 4,000, platelets
Sigma-Aldrich
Poly(ethylenglykol), average mol wt 400
Sigma-Aldrich
Poly(ethylenglykol), average Mn 20,000
Sigma-Aldrich
Poly(ethylenglykol), 35,000
Sigma-Aldrich
Kollisolv® PEG E 400
Sigma-Aldrich
Polyethylenglycol-Lösung, Hybri-Max, 50 % (w/v), average mol wt 1,450, 0.2 μm filtered, BioReagent, suitable for hybridoma
Sigma-Aldrich
Poly(ethylenoxid), average Mv ~4,000,000 (nominal), contains <1000 ppm BHT as inhibitor
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 35,000
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, for molecular biology, 6,000
Sigma-Aldrich
Poly(ethylenoxid), average Mv ~1,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenoxid), average Mv 200,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 400
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 6,000
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 2,000
Sigma-Aldrich
Poly(ethylenglykol), average mol wt 1,450
Sigma-Aldrich
Poly(ethylenoxid), average Mv 400,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenglykol), average Mn 600, waxy solid (moist)
Sigma-Aldrich
Poly(ethylenoxid), average Mv ~300,000 (nominal), powder
Sigma-Aldrich
Poly(ethylenglykol), BioUltra, 20,000
Sigma-Aldrich
Poly(ethylenglykol), average Mn 950-1,050
Sigma-Aldrich
Poly(ethylenoxid), average Mv ~900,000 (nominal), powder